All studies involving NZB/BlNJ


Filter by:
Data set Procedure What's in this data set Panel Sex Age (weeks) Year
Albers1 lipid profile
with high-fat diet
Cholesterol, HDL, non-HDL, triglycerides, phospholipids. 4h fast, plasma. Baseline vs. high-fat diet (6wks). inbred   (15) both 6-14wks 1999
Albers1 protein activity assessment
with high-fat diet
Phospholipid transfer protein activity. 4h fast. inbred   (15) both 6-14wks 1999
Bachmanov1 body weight Body weight inbred   (13) m 7-8wks 2011
Bachmanov1 bottle choice test Sodium chloride solution taste threshold. Fluid intake. inbred   (13) m 7-8wks 2011
Bachmanov1 intake monitoring Water intake. Daily. inbred   (13) m 7-8wks 2011
Benavides1 genotype assessment Gpr84 allele assessment. PCR, sequencing. inbred w/CC8   (58) both 6wks 2013
Benoist1 immune cell quantification Regulatory T cells (Treg), thymus, spleen. inbred   (33) m 5-6wks 2007
Berndt1 ventilator
with methacholine
Airway resistance. Baseline vs. methacholine-challenged (several doses). inbred   (37) both 9-12wks 2010
Boon1 body weight
with influenza A (H5N1) virus
Influenza A (H5N1) virus (several doses) vs. baseline. inbred   (23) f 6-9wks 2011
Boon1 health assessment
with influenza A (H5N1) virus
Survival rate, influenza A (H5N1) virus (several doses). Strain H5N1 susceptibility score. inbred   (23) f 6-9wks 2011
Broad2 genotyping SNP profiling, 131,000+ genomic locations, 1-19,X. inbred   (89) 2009
CGD-MDA1 genotyping SNP profiling, 470,000+ genomic locations, 1-19,X,Y,MT. inbred   (142) m 2014
CGDpheno1 body size and weight Body weight and length. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 complete blood count Hematology. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 DXA Body mass, fat mass, lean mass, bone mineral density. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 lipid profile Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 metabolic panel Clinical blood chemistry (plasma). 4h fast. inbred w/CC8   (72) both 10-13wks 2009
Chen1 immune cell quantification Natural killer T cells in peripheral blood, spleen, thymus. inbred   (38) both 8-10wks 2011
Churchill1 DXA Body mass, fat mass, lean mass, bone mineral density and content, bone area. F1 8way   (63) both 7-8wks 2004
Churchill1 muscle weights Quadriceps muscle. F1 8way   (63) both 7-8wks 2004
Churchill1 organ dimensions Ear length (pinal). F1 8way   (63) both 7-8wks 2004
Crabbe3 body weight
with ethanol
Body weight inbred   (22) both 9-17wks 2003
Crabbe3 rotarod
with ethanol
Baseline and ethanol i.p. 3 fixed speeds (several doses) and accelerating. inbred   (22) both 9-17wks 2003
Crabbe4 alcohol quantification
with ethanol
Blood alcohol concentration after ethanol 2 g/kg i.p., several timepoints. inbred   (21) both 9-17wks 2003
Crabbe4 dowel balance test
with ethanol
Latency to fall 0 min and 30 min post-injection, 2 widths. Ethanol 2 g/kg. inbred   (21) both 9-17wks 2003
Crabbe4 grip strength
with ethanol
Baseline vs. 30 min after ethanol 2 g/kg i.p. inbred   (21) both 9-17wks 2003
Crabbe4 vertical wire mesh
with ethanol
Latency to fall 30 min post-injection. Ethanol 2 g/kg i.p. inbred   (21) both 9-17wks 2003
Dietrich1 in vitro assay
with Bacillus anthracis lethal toxin
Bacillus anthracis lethal toxin (anthrax) susceptibility. inbred   (50) f 6-8wks* 1998
DiPetrillo1 urinalysis Microalbumin, creatinine, ratio. inbred w/CC7   (34) m 10wks 2012
Donahue1 DXA Body mass, fat mass, lean mass, bone mineral density and content, craniofacial dimensions. inbred w/CC7   (30) both 15-16wks 2002
Donahue1 hormone quantification Osteocalcin, insulin-like growth factor 1. inbred w/CC7   (30) both 15-16wks 2002
Donahue1 metabolic panel Thyroxine (serum). inbred w/CC7   (30) both 15-16wks 2002
Donahue2 biomechanical test Bone strength. inbred   (10) both 16wks 2004
Donahue2 body weight Body weight inbred   (10) both 16wks 2004
Donahue2 bone dimensions Femur. inbred   (10) both 16wks 2004
Donahue2 computed tomography Bone morphology (femur). inbred   (10) both 16wks 2004
Donahue2 DXA Femur bone mineral density and content, thigh cross sectional areas. inbred   (10) both 16wks 2004
Donahue2 muscle weights Quadriceps muscle. inbred   (10) both 16wks 2004
Finn1 bottle choice test
with ethanol
Voluntary consumption of ethanol, and ethanol with saccharin (several doses in water). inbred   (22) both 8-12wks 2007
Graubert1 complete blood count
with ENU
Hematology. inbred   (20) both 9wks; 12-64wks 2006
Graubert1 histopathology
with ENU
Tumor growth frequency rates. ENU mutagen 100 mg/kg vs. control. inbred   (20) both 9wks; 12-64wks 2006
Gros2 health assessment
with Plasmodium chabaudi
Survival score and susceptibility, Plasmodium chabaudi. inbred   (25) both 8-10wks 2012
Gros2 microscopy
with Plasmodium chabaudi
Percent of Plasmodium chabaudi-infected erythrocytes in blood. inbred   (25) both 8-10wks 2012
Hampton1 ECG Heart rate and wave intervals. Conscious. inbred   (17) both 9-12wks 2001
Haston1 bronchoalveolar lavage assessment
with radiation
Bronchoalveolar cell differential after exposure to radiation (18 Gy). inbred   (26) both 15-36wks 2012
Haston1 health assessment
with radiation
Survival rate and health assessment after exposure to radiation. Number of days without respiratory distress (max 26 wks). inbred   (26) both 15-36wks 2012
Haston1 histopathology
with radiation
Post exposure to radiation. inbred   (26) both 15-36wks 2012
Hawes1 ophthalmoscopy Retinal fundoscopic examination. inbred w/CC7   (41) both 6-7wks 2008
Hawes1 slit lamp Eye morphology. Frequency rates of disorders. inbred w/CC7   (41) both 6-7wks 2008
HMDPpheno1 DXA Bone mineral density (whole body, femur, spine). HMDP   (96) m 16wks 2011
HMDPpheno2 lipid profile Cholesterol, HDL, non-HDL, triglycerides, free fatty acids. 16h fast, plasma. HMDP   (99) m 16wks 2010
HMDPpheno2 NMR Percent fat. HMDP   (99) m 16wks 2010
HMDPpheno3 tail cuff Heart rate and blood pressure. Conscious mice. HMDP   (58) m 9-10wks 2012
HMDPpheno4 fear conditioning test Contextual fear, cued fear. HMDP   (94) m 10wks 2011
Jax2 MHC haplotype tissue typing Major histocompatibility complex (MHC) H2 haplotype. inbred   (56) both 2000
Jax3 colony observation Reproductive performance. inbred   (33) f various 1991
Jax4 colony observation Appearance, coat color inbred   (61) both 2006
Jax5 colony observation Reproductive performance. inbred   (35) f various 2009
Kliethermes1 hole board test Head dipping and other activity measures, hole board with and without objects in two of the holes. 10 min test. inbred   (14) both 8wks 2006
Kliethermes1 monitoring system Activity in a novel environment. Distance traveled, number of rears. 30 min test. inbred   (14) both 8wks 2006
Kliethermes1 two chamber assay Novel environment preference. Activity in familiar and novel compartments. 20 min test. inbred   (14) both 8wks 2006
Kliethermes1 Y-maze Spontaneous alternation. inbred   (14) both 8wks 2006
Kumar2 open field test Distance traveled, after first 10 min and after 55 min. other   (58) both 7-26wks 2019
Kumar3 body weight Body weight inbred w/CC8   (62) both 8-14wks 2021
Kumar3 open field test Locomotor activity and grooming behavior. inbred w/CC8   (62) both 8-14wks 2021
Kumar4 body size and weight Body length measurements. inbred w/CC8   (62) both 10-20 wks 2021
Kumar4 gait analysis Angular velocity, Stride speed, Step length, Step width, and other gait metrics. inbred w/CC8   (62) both 10-20 wks 2021
Kumar4 open field test Distance traveled. inbred w/CC8   (62) both 10-20 wks 2021
Lightfoot1 body weight Body weight inbred   (41) both 8-9wks 2010
Lightfoot1 running wheel monitoring Distance, duration, speed. inbred   (41) both 8-9wks 2010
Massett1 body weight Body weight inbred   (34) both 8wks 2012
Massett1 treadmill endurance test Duration, distance, work. inbred   (34) both 8wks 2012
Maurer1 body weight
with atenolol, isoproterenol
Isoproterenol or atenolol vs. control. inbred   (23) m 10-12wks 2009
Maurer1 ECG
with atenolol, isoproterenol
Heart rate and wave amplitudes and intervals. Unconscious. Isoproterenol or atenolol vs. control. inbred   (23) m 10-12wks 2009
Maurer1 organ weights
with atenolol, isoproterenol
Heart, atria, ventricle weights. Isoproterenol or atenolol vs. control. inbred   (23) m 10-12wks 2009
Maurer1 tail cuff
with atenolol, isoproterenol
Heart rate and blood pressure. Conscious mice. Isoproterenol or atenolol vs. control. inbred   (23) m 10-12wks 2009
Mitchell1 bottle choice test Sucrose vs. water. inbred   (15) m 5-7wks 2010
Mitchell1 go/no-go task Pre-cue, go cue. no-go cue. Discrimination index. inbred   (15) m 5-7wks 2010
Mitchell1 monitoring system Locomotor activity. inbred   (15) m 5-7wks 2010
Mogil3 nociception assay von Frey nociception test, baseline and after spared nerve injury (SNI) surgery as a hypersensitizer. inbred   (18) both 7-12wks 2012
Moy1 three chamber assay Sociability and preference for social novelty. Autism-relevant behaviors. inbred   (17) m 6-7wks 2008
Naggert1 body weight
with high-fat diet
High-fat diet for 8wks. inbred w/CC7   (43) both 5, 21 wks 2003
Naggert1 DXA
with high-fat diet
Body mass, fat mass, lean mass, bone mineral density and content after 8wks on high-fat diet. inbred w/CC7   (43) both 5, 21 wks 2003
Naggert1 hormone quantification
with high-fat diet
Insulin and leptin after 18wks on high-fat diet. Multiple readings per animal were averaged. inbred w/CC7   (43) both 5, 21 wks 2003
Naggert1 metabolic panel
with high-fat diet
Glucose (plasma). Baseline vs. high-fat diet (17wks). 4h fast. inbred w/CC7   (43) both 5, 21 wks 2003
Paigen1 body weight
with high-fat diet
Baseline vs. high-fat diet for 8wks. inbred   (44) both 15-19wks 2000
Paigen1 histopathology
with high-fat diet
Gallstone, gallbladder, and atherosclerosis lesion histopathology after 8wks on high-fat diet. inbred   (44) both 15-19wks 2000
Paigen1 lipid profile
with high-fat diet
Cholesterol, HDL, non-HDL. 4h fast, plasma. Hepatic lipids. 8wks on high-fat diet. inbred   (44) both 15-19wks 2000
Paigen1 metabolic panel
with high-fat diet
Alanine transaminase, bile salts (plasma) after 8wks on high-fat diet. 4h fast. inbred   (44) both 15-19wks 2000
Paigen1 organ dimensions
with high-fat diet
Gallbladder volume after 8wks on high-fat diet. inbred   (44) both 15-19wks 2000
Paigen1 organ weights
with high-fat diet
Liver weight after 8wks on high-fat diet. inbred   (44) both 15-19wks 2000
Paigen2 histopathology
with high-fat diet
Aortic lesion size histopathology. Baseline vs. high-fat diet (17wks). inbred w/CC7   (43) both 7-9wks, 24-27wks 2002
Paigen2 lipid profile
with high-fat diet
Cholesterol, HDL, non-HDL, triglycerides. Baseline vs. high-fat diet (17wks). 4h fast, plasma. inbred w/CC7   (43) both 7-9wks, 24-27wks 2002
Paigen4 lipid profile Cholesterol, HDL, non-HDL, triglycerides. 4h fast, plasma. inbred w/CC7   (43) both 10wks 2002
Peters1 coagulation test Fibrinogen. inbred w/CC7   (43) both 10wks 2001
Peters1 complete blood count Hematology. inbred w/CC7   (43) both 10wks 2001
Pletcher1 body weight Body weight inbred   (32) m 7-9wks 2007
Pletcher1 hormone quantification Corticosterone (serum). inbred   (32) m 7-9wks 2007
Pletcher1 open field test Locomotor and anxiety-related behavior. 10 min test. inbred   (32) m 7-9wks 2007
Pletcher1 tail suspension test Immobility percentage. inbred   (32) m 7-9wks 2007
Reed1 body size and weight Body weight, body length, body mass index. inbred   (28) m 8, 12 wks 2009
Reed1 fat pad weights Epididymal, retroperitoneal. inbred   (28) m 8, 12 wks 2009
Reed1 organ weights Heart, kidney weights. inbred   (28) m 8, 12 wks 2009
Richfield1 neurotransmitter quantification Neurotransmitters. Molecular measures. inbred   (15) m 7-9wks 2003
Richfield1 open field test Locomotor activity. 3 day trials. 45 min sessions. inbred   (15) m 7-9wks 2003
Sanger4 genotyping SNP profiling, 80,000,000+ genomic locations. SNPs and indels. 1-19,X. inbred   (37) both 2017
Schonfeld1 body weight Body weight inbred   (11) both 8-10wks 2005
Schonfeld1 DXA Fat mass. inbred   (11) both 8-10wks 2005
Schonfeld1 glucose tolerance 0 to 120 min after 10% glucose i.p. 5h fast. inbred   (11) both 8-10wks 2005
Schonfeld1 hormone quantification Insulin level, 30 min post-injection in glucose tolerance test. 10% glucose. 5h fast. inbred   (11) both 8-10wks 2005
Schonfeld1 insulin tolerance 0 to 120 min after insulin i.p. 5h fast. inbred   (11) both 8-10wks 2005
Schonfeld1 lipid profile Cholesterol, triglycerides, free fatty acids, phospholipids. 5h fast, plasma. Hepatic triglycerides. inbred   (11) both 8-10wks 2005
Schonfeld1 metabolic panel Glucose, beta-hydroxybutyrate (plasma). No fast. inbred   (11) both 8-10wks 2005
Schonfeld1 organ weights Liver weight. inbred   (11) both 8-10wks 2005
Seburn1 body weight Body weight inbred   (16) both 7-9wks 2001
Seburn1 intake monitoring Food, caloric, and water intake. Daily. inbred   (16) both 7-9wks 2001
Seburn1 monitoring system Locomotor activity and energy metabolism. 24h test. inbred   (16) both 7-9wks 2001
Shockley1 body weight
with high-fat diet
High-fat diet for 4wks vs. control. inbred   (10) both 10-13wks 2008
Shockley1 lipid profile
with high-fat diet
Cholesterol, HDL, triglycerides, fatty acids. High-fat diet (4wks) vs. control. 5h fast, serum. inbred   (10) both 10-13wks 2008
Shockley1 metabolic panel
with high-fat diet
Clinical blood chemistry measures (serum). High-fat diet (4wks) vs. control. inbred   (10) both 10-13wks 2008
Tarantino1 body weight
with cocaine
Body weight inbred   (45) m 8-11wks 2015
Tarantino1 open field test
with cocaine
Locomotor activity. Baseline (saline) vs. cocaine 20 mg/kg i.p. 30 min test. inbred   (45) m 8-11wks 2015
Tordoff1 body weight Body weight during testing. inbred   (28) m 9wks 2001
Tordoff1 bottle choice test Various salt solutions (several concentrations) vs. water. inbred   (28) m 9wks 2001
Tordoff2 body weight Body weight inbred   (28) m 4-12wks 2001
Tordoff2 intake monitoring Food intake, water intake. Daily. inbred   (28) m 4-12wks 2001
Tordoff3 body weight Body weight inbred w/CC7   (40) both 9-15wks 2002
Tordoff3 bottle choice test Various salt solutions (several concentrations) vs. water. inbred w/CC7   (40) both 9-15wks 2002
Tordoff3 DXA Body mass, fat mass, lean mass, bone mineral density and content. inbred w/CC7   (40) both 9-15wks 2002
Tordoff3 metabolic panel Ionized and total blood calcium, blood pH. inbred w/CC7   (40) both 9-15wks 2002
Tordoff3 monitoring system Bleeding time to collect approx 30 µL. inbred w/CC7   (40) both 9-15wks 2002
Trullas1 elevated plus maze Exploratory and anxiety-related behaviors. 5 min test. inbred   (16) m 6-8wks 1993
Trullas1 hormone quantification Corticosterone levels (plasma). Baseline vs. after stress (30 min in restraining cage). inbred   (16) m 6-8wks 1993
Trullas1 monitoring system Novelty-induced fear test. Eating inhibition due to novelty of environment. 10 min test. inbred   (16) m 6-8wks 1993
Trullas1 open field test Locomotor activity under dim lights vs. bright lights. 5 min test. inbred   (16) m 6-8wks 1993
UCLA1 genotyping SNP profiling, 132,000+ genomic locations, 1-19,X HMDP   (248) both 2018
Vinyard1 body weight Body weight inbred   (21) both 6-8wks 2009
Vinyard1 bone dimensions Craniofacial bone dimensions. inbred   (21) both 6-8wks 2009
Vulpe1 mineral quantification Liver mineral levels. Iron, copper, zinc. Iron homeostasis. inbred   (18) both 8wks 2010
Vulpe1 transferrin quantification Diferric transferrin (plasma). inbred   (18) both 8wks 2010
Wahlsten1 elevated plus maze Locomotor, exploratory, and anxiety-related behavior. inbred   (21) both 9, 12 wks 2003
Wahlsten1 histopathology Corpus callosum, hippocampus, anterior commisure. inbred   (21) both 9, 12 wks 2003
Wahlsten1 open field test Locomotor, exploratory, and anxiety-related behavior. 5 min test. inbred   (21) both 9, 12 wks 2003
Wahlsten1 organ weights Brain weight. inbred   (21) both 9, 12 wks 2003
Wahlsten2 behavior observation Wildness scoring during various phenotyping tests. inbred   (21) both 10-12wks 2003
Willott1 acoustic startle test Acoustic startle response, prepulse inhibition. inbred w/CC7   (40) both 5-6wks 2002
Willott1 body weight Body weight inbred w/CC7   (40) both 5-6wks 2002
Wiltshire1 elevated plus maze Locomotor activity. inbred   (38) both 12-14wks 2010
Wiltshire1 light-dark box Light-dark test. Anxiety-related behavior. inbred   (38) both 12-14wks 2010
Wiltshire1 open field test Locomotor activity. inbred   (38) both 12-14wks 2010
Wiltshire2 drug and metabolite quantification
with fluoxetine
Fluoxetine and norfluoxetine concentration (serum) after fluoxetine. inbred   (30) m 9-11wks 2011
Wiltshire2 open field test
with fluoxetine
Locomotor activity, exploratory and anxiety-related behavior. Fluoxetine-treated vs. control. 7 min test. inbred   (30) m 9-11wks 2011
Wiltshire2 tail suspension test
with fluoxetine
Immobility. Fluoxetine-treated vs. control. 5 min test. inbred   (30) m 9-11wks 2011
Wiltshire3 biomarker quantification
with fluoxetine
Brain tissue survey of 30 biochemical analytes. Fluoxetine-treated vs. control. 21d. inbred   (30) m 10-11wks 2011
Wiltshire4 immune cell quantification
with BEZ235, doxorubicin, idarubicin, selumetinib
In vitro study of 4 cancer chemotherapies (BEZ235, doxorubicin, idarubicin, selumetinib) vs. control. Effect on immune cells. Normalized data. inbred w/CC7   (36) m 10wks 2015
Zheng1 tympanometry Middle ear function. inbred   (61) both 15-51d 2008
Zimmermann1 body weight inbred   (30) both 7-15 wks 2020
Zimmermann1 intake monitoring Food and water intake; 2-day test, second day data analyzed during 12:12h light and dark periods. inbred   (30) both 7-15 wks 2020
Zimmermann1 monitoring system Voluntary activity and energy expenditure. 2-day test, second day data analyzed during 12:12h light and dark periods. inbred   (30) both 7-15 wks 2020